FeesSafety
Pluang+

Bank of America starts Viridian Therapeutics at 'buy' with $47 target on promising thyroid eye disease drugs

Analyst Insights
20 Nov 2026, 02:14 WIB
Proactive Investors
View Source
Bullish
Bank of America starts Viridian Therapeutics at 'buy' with $47 target on promising thyroid eye disease drugs

Bank of America initiated coverage of Viridian Therapeutics with a 'buy' rating and a $47 price target, highlighting the potential of its thyroid eye disease treatments to capture significant market share. Lumvoa, a new treatment launched in July, shows strong early sales and could challenge the current market leader, Tepezza, with a shorter treatment course. The brokerage also sees promise in elegrobart, an investigational drug for chronic thyroid eye disease, expected to be submitted for approval in early 2027. These drugs could significantly expand treatment options in an underserved market, with peak sales forecasts of $1.3 billion for Lumvoa and $1.7 billion for elegrobart.

Viridian Therapeutics' recent initiation by Bank of America with a buy rating and $47 target is presented here with Pluang's health sector data for context. For readers following health stocks, here is Pluang's market snapshot as of Nov 20, 2026 07:01 WIB: out of 150 priced US health stocks, only 20 rose while 130 fell. Among notable movers, UNH traded at USD 328.49 with a 6.12% decline and a buy order activity of 67%, contrasting with TNGX which gained 5.89% to USD 23.18 and had a much shorter typical hold time of 5 days.

More News

S&P 500's four-week drop after record high signals potential long-term gains, not a bear market.

S&P 500's four-week drop after record high signals potential long-term gains, not a bear market.

The S&P 500 recently experienced a four-week losing streak following a record high, dropping about 8% from its peak. Historically, such declines have often been healthy pullbacks rather than signs of a bear market, with the index showing gains six an...

Market News
Bullish
1 hour ago
Universal Technical Institute's revenue rises but profit falls, shares drop nearly 9%.

Universal Technical Institute's revenue rises but profit falls, shares drop nearly 9%.

Universal Technical Institute (UTI) reported a 6% increase in fourth-quarter revenue to $235.9 million, driven by a rise in full-time students. However, net income fell nearly 4% to just over $18 million, missing analyst earnings per share estimates....

Company Fundamentals
Bearish
1 hour ago
Michael Burry warns investors on risks in CoreWeave, Nebius, Nvidia, and chip stocks amid falling prices.

Michael Burry warns investors on risks in CoreWeave, Nebius, Nvidia, and chip stocks amid falling prices.

Investor Michael Burry highlighted risks in CoreWeave, Nebius, Nvidia, and semiconductor stocks, noting significant price drops due to rising borrowing costs and potential long-term challenges for Nvidia's competitive edge. CoreWeave and Nebius have ...

Market News
Bearish
1 hour ago
AMD's AI data center revenue nearly doubles, positioning it to challenge Nvidia's dominance.

AMD's AI data center revenue nearly doubles, positioning it to challenge Nvidia's dominance.

AMD is gaining ground on Nvidia in the AI chip market, with its data center revenue nearly doubling year over year in Q3 and overall revenue up 45%. Nvidia faces leadership uncertainty after former CEO Jensen Huang's departure, creating an opportunit...

Market News
Bullish
1 hour ago
Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's new prostate cancer drug shows 75% response in early trials, boosting its strong pipeline.

Johnson & Johnson's investigational drug JNJ-6143, acquired through a $3.05 billion purchase of Halda Therapeutics, demonstrated a 75% overall response rate in a Phase 1 trial for metastatic castration-resistant prostate cancer. This promising early ...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App